Tdp 43 Proteinopathy In Als represents a key pathological mechanism in neurodegenerative diseases. This page explores the molecular and cellular processes involved, their contribution to disease progression, and therapeutic implications.
TDP-43 (TAR DNA-binding protein 43) is a nuclear RNA/DNA-binding protein that is central to the pathogenesis of most cases of Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD). Pathological TDP-43 aggregation is found in approximately 95% of ALS cases and 50% of FTD cases, making it a key therapeutic target. [1]
TDP-43 is a heterogeneous nuclear ribonucleoprotein (hnRNP) with essential functions: [2]
Normal localization: Predominantly nuclear, with some cytoplasmic localization for transport. [3]
In disease, TDP-43 undergoes characteristic changes: [4]
Nuclear TDP-43 loss disrupts: [5]
Splicing dysregulation: [6]
RNA processing defects: [7]
Cytoplasmic TDP-43 aggregates cause: [8]
Stress granule dysfunction: [9]
Mitochondrial dysfunction: [10]
Nuclear pore pathology: [11]
| Gene | Mutation Effect | % of ALS | [12]
|------|---------------|----------| [13]
| TARDBP | Autosomal dominant | ~3-5% | [14]
| FUS | Autosomal dominant | ~3-5% |
| C9orf72 | Hexanucleotide repeat | ~40% |
| TIA1 | Stress granule regulation | ~1% |
TDP-43 aggregation inhibitors
RNA-targeted therapies
Stress granule modulators
Mitochondrial protectors
Autophagy enhancers
The study of Tdp 43 Proteinopathy In Als has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
🟡 Moderate Confidence
| Dimension | Score |
|---|---|
| Supporting Studies | 15 references |
| Replication | 0% |
| Effect Sizes | 25% |
| Contradicting Evidence | 0% |
| Mechanistic Completeness | 75% |
Overall Confidence: 45%
TDP-43 contains multiple domains that contribute to its aggregation propensity:
Pathological TDP-43 is characterized by specific PTMs:
| Modification | Site | Significance |
|---|---|---|
| Phosphorylation | Ser409/Ser410 | Disease-specific, drives aggregation |
| Phosphorylation | Ser379/Ser403/Ser409 | Multiple sites in patient tissue |
| Ubiquitination | Lys residues | Marks for proteasomal degradation |
| Sumoylation | Lys residues | May promote aggregation |
| C-terminal truncation | Various sites | Generates toxic fragments |
TDP-43 regulates splicing and stability of critical neuronal transcripts:
| Function | Key Targets | Disease Relevance |
|---|---|---|
| Neuronal development | UNC13A, STX3, PRKN | Developmental defects |
| Synaptic function | SYN1, DLGL1, CACNA2D3 | Synaptic dysfunction |
| Mitochondrial function | NDUFA2, ATP5F1B | Energy deficits |
| Axonal transport | DYNC1H1, KIF5C | Axonal pathology |
| RNA splicing | Cryptic exons in multiple genes | Global splicing disruption |
One of the most significant consequences of TDP-43 loss:
| Approach | Mechanism | Stage |
|---|---|---|
| ASOs for TARDBP | Reduce mutant TDP-43 | Preclinical |
| Splicing modulators | Prevent cryptic exon inclusion | Preclinical |
| RNA stabilizers | Enhance nuclear TDP-43 function | Preclinical |
| Approach | Mechanism | Stage |
|---|---|---|
| Aggregation inhibitors | Block protein-protein interactions | Preclinical |
| Small molecule stabilizers | Prevent misfolding | Preclinical |
| Antibody therapies | Anti-TDP-43 antibodies | Preclinical |
| Approach | Mechanism | Stage |
|---|---|---|
| Autophagy enhancers | TFEB activators | Preclinical |
| Proteasome enhancers | Increase degradation | Preclinical |
| Immunotherapies | Antibody-mediated clearance | Preclinical |
Arai T, et al. (2006) TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. 2006. ↩︎
Sreedharan J, et al. (2008) TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. 2008. ↩︎
Lagier-Tourenne C, et al. '(2010) ALS associated with TDP-43: a new role for an old protein'. 2010. ↩︎
Johnson BS, et al. (2009) TDP-43 is intrinsically aggregation-prone, and amyotrophic lateral sclerosis-linked mutations accelerate aggregation and increase toxicity. 2009. ↩︎
Buratti E, et al. (2005) Nuclear factor TDP-43 can affect selected gene expression via splicing inhibition. 2005. ↩︎
Sephton CF, et al. '(2011) TDP-43 in central nervous system development and function: clues to TDP-43-associated neurodegeneration'. 2011. ↩︎
Al-Chalabi A, et al. (2012) The genetics and neuropathology of amyotrophic lateral sclerosis. 2012. ↩︎
Liu Y, et al. (2017) TDP-43 pathology in Alzheimer's disease. 2017. ↩︎
Rascovsky M, et al. (2011) Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. 2011. ↩︎
Chio A, et al. '(2019) Global epidemiology of ALS: a systematic review of the literature'. 2019. ↩︎
Gao FB, et al. '(2019) Molecular mechanisms of TDP-43 aggregation in neurodegenerative diseases: potential targets for intervention'. 2019. ↩︎
Prasad A, et al. (2019) Molecular mechanisms of TDP-43 in neurodegeneration. 2019. ↩︎
Hunter M, et al. '(2021) TDP-43 pathology in neurodegenerative disease: a review'. 2021. ↩︎
Frontini M, et al. '(2022) TDP-43 and ALS: latest evidence and therapeutic implications'. 2022. ↩︎